Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SBEV vs KTTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KTTA Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 5–2 Matrix Metrics)

KTTA Overall Winner 6-Pillar Tally: SBEV 0 – 5 KTTA (1 Tie) Matrix Metrics: SBEV 2 – 5 KTTA

As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) is the stronger overall head-to-head candidate over Splash Beverage Group, Inc. (SBEV) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SBEV carries a Unified Composite Score of 36.4/100 (SELL) at $0.47 (N/M Forward P/E, -23888.5% operating margin), whereas KTTA carries 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SBEV trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 66.6); meanwhile KTTA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SBEV vs KTTA
SBEV NYSE American
Splash Beverage Group, Inc.
Beverages
$0.47
+10.94% 1D
Market Cap $2.7M
TTM Revenue $8,684
Forward P/E N/M
Beta / 30D Vol -1.41β · 136% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 15.0 Fund 32.0 Flow 44.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (37.2% over 20 days), RSI 67
RSI-14: 66.6 · SMA20: $0.39 · SMA50: $0.27
KTTA NASDAQ Head-to-Head Winner
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap $17.7M
TTM Revenue $486,559
Forward P/E N/M
Beta / 30D Vol 0.68β · 185% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 20.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.1%) with fading momentum, RSI 50
RSI-14: 49.6 · SMA20: $0.48 · SMA50: $0.47

6-Pillar Scorecard Institutional Category Breakdown (SBEV 0 – 5 KTTA)

Columns: Metric · SBEV · KTTA
1. Valuation Multiples KTTA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 36.3x
2. Growth & Scale KTTA
Revenue Growth (YoY) -93.8% +1498.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $8,684 $486,559
Market Cap $2.7M $17.7M
3. Profitability & Quality KTTA
Gross Margin N/A -0.5%
Operating Margin -23888.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1130.2% -88.8%
4. Balance Sheet & Cash Flow KTTA
Cash Generation (TTM) -$5.0M -$18M
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.0M Net Debt $1.31 Book/Sh · -88.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning KTTA
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Beverages - Wineries & Distilleries Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SBEV (2) vs KTTA (5)
Institutional Metric SBEV KTTA Criterion Row Edge
Market Capitalization
Scale
$2.7M $17.7M Larger Scale KTTA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-93.8% +1498.1% Higher Growth KTTA
Operating Margin (TTM)
Profitability
-23888.5% 0.0% Higher Margin KTTA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1130.2% -88.8% Higher ROE KTTA
52-Week Range Position
Momentum
12% ($0–$3) 11% ($0–$2) Stronger Trend SBEV
Beta / 30D Volatility
Risk Regime
-1.41β · 136% Vol 0.68β · 185% Vol Lower Realized Risk SBEV
Unified Institutional Score
Composite Signal
36.4 / 100 (SELL) 42.1 / 100 (HOLD) Higher Composite KTTA
Trailing 12M Revenue (USD)
Operating Scale
$8,684 $486,559 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -0.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 36.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$5.0M ($6.0M Net Debt) -$18M ($1.31 Book/Sh · -88.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SBEV +345.36 pp
SBEV: +358.21% · KTTA: +12.85%
3M Horizon SBEV +123.82 pp
SBEV: +92.53% · KTTA: -31.29%
6M Horizon SBEV +45.73 pp
SBEV: +18.92% · KTTA: -26.81%
1Y Horizon KTTA +61.13 pp
SBEV: -47.79% · KTTA: +13.34%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SBEV Revenue KTTA Revenue SBEV Op. Margin KTTA Op. Margin Margin Leader
FY2018 $0M N/A 5.1% N/A SBEV
FY2019 $0M N/A -22009.4% N/A SBEV
FY2020 $0M N/A -767.9% N/A SBEV
FY2021 $10M $0M -257.0% -29925.7% SBEV
FY2022 $20M $0M -118.3% -2587.3% SBEV
FY2023 $20M N/A -81.1% N/A SBEV
FY2024 $0M N/A -1235.6% N/A SBEV
FY2025 $0M N/A -19415.6% N/A SBEV

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SBEV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SBEV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KTTA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SBEV Moat Profile Cyclical / Execution-Driven Positioning
Beverages - Wineries & Distilleries Operator
Competes within the Beverages - Wineries & Distilleries value chain with $2.7M market capitalization and -23888.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KTTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $17.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SBEV vs KTTA Key Questions & Quantitative Answers

As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) is the stronger overall head-to-head candidate over Splash Beverage Group, Inc. (SBEV) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SBEV carries a Unified Composite Score of 36.4/100 (SELL) at $0.47 (N/M Forward P/E, -23888.5% operating margin), whereas KTTA carries 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SBEV trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 66.6); meanwhile KTTA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KTTA leads the Growth & Scale pillar: SBEV posts -93.8% YoY revenue growth and +0.0% YoY earnings growth on $8,684 TTM revenue (N/A gross margin, -23888.5% operating margin), compared with KTTA at +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SBEV cumulative revenue shifted +100.0% while KTTA shifted N/A. In operating R&D and SG&A reinvestment, SBEV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KTTA.

KTTA screens cheaper on headline valuation multiples. SBEV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SBEV (-1130.2% ROE) versus KTTA (-88.8% ROE) capital efficiency.

In options market volatility and institutional positioning, SBEV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.41β · 136% Vol realized risk). By comparison, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.